CN1551783B - 类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用 - Google Patents

类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用 Download PDF

Info

Publication number
CN1551783B
CN1551783B CN028174437A CN02817443A CN1551783B CN 1551783 B CN1551783 B CN 1551783B CN 028174437 A CN028174437 A CN 028174437A CN 02817443 A CN02817443 A CN 02817443A CN 1551783 B CN1551783 B CN 1551783B
Authority
CN
China
Prior art keywords
antibody
seq
application
cells
peptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028174437A
Other languages
English (en)
Chinese (zh)
Other versions
CN1551783A (zh
Inventor
罗伯特·林赛·雷森
罗莎奈·多箩西·邓恩
布恩·华·安德烈·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blood Pump Pte Ltd
Original Assignee
Immune System Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Therapeutics Ltd filed Critical Immune System Therapeutics Ltd
Publication of CN1551783A publication Critical patent/CN1551783A/zh
Application granted granted Critical
Publication of CN1551783B publication Critical patent/CN1551783B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN028174437A 2001-07-06 2002-07-05 类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用 Expired - Lifetime CN1551783B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6179A AUPR617901A0 (en) 2001-07-06 2001-07-06 Method for treating multiple myeloma
AUPR6179 2001-07-06
PCT/AU2002/000896 WO2003004056A1 (en) 2001-07-06 2002-07-05 Method for treating multiple myeloma

Publications (2)

Publication Number Publication Date
CN1551783A CN1551783A (zh) 2004-12-01
CN1551783B true CN1551783B (zh) 2010-11-03

Family

ID=3830143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028174437A Expired - Lifetime CN1551783B (zh) 2001-07-06 2002-07-05 类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用

Country Status (13)

Country Link
US (3) US7344715B2 (enExample)
EP (1) EP1414492B1 (enExample)
JP (1) JP4535424B2 (enExample)
CN (1) CN1551783B (enExample)
AU (1) AUPR617901A0 (enExample)
CA (1) CA2461989C (enExample)
DE (1) DE60223688T2 (enExample)
DK (1) DK1414492T3 (enExample)
ES (1) ES2296952T3 (enExample)
MX (1) MXPA04000130A (enExample)
NZ (1) NZ530099A (enExample)
WO (1) WO2003004056A1 (enExample)
ZA (1) ZA200400959B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
WO2005082409A1 (en) * 2004-02-27 2005-09-09 Pacmab Limited Target for b-cell disorders
RU2393483C2 (ru) * 2004-12-23 2010-06-27 Ф.Хоффманн-Ля Рош Аг Детекция терапевтического антитела у экспериментального животного
GB0608444D0 (en) * 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
WO2009099176A1 (ja) 2008-02-08 2009-08-13 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
ES2614949T3 (es) 2009-08-06 2017-06-02 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
MX360347B (es) 2010-08-17 2018-10-30 F Hoffmann La Roche Ag Star Anticuerpo anti-inmunoglobulina g1 humana.
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
PT3286223T (pt) * 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
CN109395058A (zh) * 2016-03-13 2019-03-01 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11331380B2 (en) 2016-10-20 2022-05-17 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
US20220031840A1 (en) * 2018-12-03 2022-02-03 Haemalogix Pty Ltd Method of Treatment
CA3176109A1 (en) * 2020-03-27 2021-09-30 Haemalogix Pty Ltd Composition and method
JP2023085151A (ja) * 2021-12-08 2023-06-20 株式会社八神製作所 体外ホウ素中性子反応を用いた幹細胞の分取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BOUX,H. ET AL.A TUMOR ASSCIATED ANTIGEN SPECIFIC FOR KAPPAMYELOMA CELLS.J. EXP. MED.158 5.1983,全文.
BOUX,H. ET AL.A TUMOR ASSCIATED ANTIGEN SPECIFIC FOR KAPPAMYELOMA CELLS.J. EXP. MED.158 5.1983,全文. *
DUNN R. ET AL.ANTIGEN BINDING AND CYTOTOXIC PROPERTIES OF ARECOMBINANT IMMUNOTOXININCORPORATING THE LYTIC PEPTIDE
DUNN,R. ET AL.ANTIGEN BINDING AND CYTOTOXIC PROPERTIES OF ARECOMBINANT IMMUNOTOXININCORPORATING THE LYTIC PEPTIDE,MELITTIN.IMMUNOTECHNOLOGY2 3.1996,全文. *
IZARD,M. ET AL.AN IMPROVED METHOD FOR LABELING MONOCLONALANTIBODIES WITH SAMARIUM-153:USE OF THEBIFUNCTIONALCHELATE2-(P-ISOTHIOCYANATOBENZYL)-6-METHYLDIETHYLENETRIAMINEPENTAACETIC ACID.BIOCONJUGATE CHEM3 4.1992,全文.
IZARD,M. ET AL.AN IMPROVED METHOD FOR LABELING MONOCLONALANTIBODIES WITH SAMARIUM-153:USE OF THEBIFUNCTIONALCHELATE2-(P-ISOTHIOCYANATOBENZYL)-6-METHYLDIETHYLENETRIAMINEPENTAACETIC ACID.BIOCONJUGATE CHEM3 4.1992,全文. *
WALKER , K. ET AL..A MONOCLONAL ANTIBODY WITH SELECTIVITY FORHUMAN KAPPA MYELOMA AND LYMPHOMA CELLSWHICH HAS POTENTIAL AS A THERAPEUTIC AGENT.ADV. EXP. MED. BIOL.186.1985,全文.
WALKER, K ET AL.A RAT MODEL SYSTEM FOR RADIOIMMUNODETECTIONOF KAPPA MYELOMA ANTIGEN ON MALIGNANTB CELLS.EUROP. J. MED.12 9.1986,全文.
WALKER, K ET AL.A RAT MODEL SYSTEM FOR RADIOIMMUNODETECTIONOF KAPPA MYELOMA ANTIGEN ON MALIGNANTB CELLS.EUROP. J. MED.12 9.1986,全文. *
WALKER, K. ET AL..A MONOCLONAL ANTIBODY WITH SELECTIVITY FORHUMAN KAPPA MYELOMA AND LYMPHOMA CELLSWHICH HAS POTENTIAL AS A THERAPEUTIC AGENT.ADV. EXP. MED. BIOL.186.1985,全文. *

Also Published As

Publication number Publication date
US7838041B2 (en) 2010-11-23
ES2296952T3 (es) 2008-05-01
EP1414492B1 (en) 2007-11-21
CN1551783A (zh) 2004-12-01
EP1414492A4 (en) 2005-12-21
AUPR617901A0 (en) 2001-08-02
AU2006202148A1 (en) 2006-06-08
US7344715B2 (en) 2008-03-18
NZ530099A (en) 2006-04-28
DE60223688D1 (de) 2008-01-03
DK1414492T3 (da) 2008-04-07
WO2003004056A1 (en) 2003-01-16
JP2005504018A (ja) 2005-02-10
US20090263358A1 (en) 2009-10-22
ZA200400959B (en) 2005-04-26
DE60223688T2 (de) 2008-10-30
US20040214761A1 (en) 2004-10-28
JP4535424B2 (ja) 2010-09-01
US7556803B2 (en) 2009-07-07
EP1414492A1 (en) 2004-05-06
CA2461989C (en) 2011-11-15
CA2461989A1 (en) 2003-01-16
MXPA04000130A (es) 2005-06-06
US20080199463A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
US7556803B2 (en) Method for treating multiple myeloma
KR101935088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
JP3194020B2 (ja) 腫瘍抗原特異的抗体、それを含む医薬組成物およびその抗体を産生する細胞系
JP5615169B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
CN109152798A (zh) 特异于糖基化的pd-1的抗体及其使用方法
JP2006526414A (ja) 脱免疫化抗ｃｄ３抗体
EA026990B1 (ru) Антитела, связывающиеся с человеческой клеткой dec-205
CN106620693A (zh) 新型调节剂及使用方法
CN110536901A (zh) 与髓鞘少突胶质细胞糖蛋白结合的抗体
WO2008056833A1 (en) ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
TWI776364B (zh) 一種bcma結合蛋白及其製備方法和應用
NZ276745A (en) Antibodies recognising a tumour related antigen ca55.1 its production and use
TW202402805A (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
EP2452950B1 (en) Anti-podxl2 antibody having anti-cancer activity
JP5102612B2 (ja) Ｂ細胞疾患の標的
JP7751338B2 (ja) 抗ペリオスチンヒト化モノクローナル抗体及びその製造方法と応用
CN113087796B (zh) 一种抗pd-l1抗体及其应用
US20240390418A1 (en) Anti-variable muc1* antibodies and uses thereof
AU2002344701B2 (en) Method for treating multiple myeloma
AU2002344701A1 (en) Method for treating multiple myeloma
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
CN120173102A (zh) 靶向b7h7的抗体或其抗原结合片段及其应用
HK40017293B (zh) 与髓鞘少突胶质细胞糖蛋白结合的抗体
HK1059442B (en) Human monoclonal antibodies to dendritic cells
HK1059442A1 (en) Human monoclonal antibodies to dendritic cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161017

Address after: New South Wales, Australia

Patentee after: Blood pump Pte. Ltd.

Address before: New South Wales, Australia

Patentee before: Immune System Therapeutics Ltd.

CX01 Expiry of patent term

Granted publication date: 20101103

CX01 Expiry of patent term